ClinicalTrials.gg
RecruitingNCT07236502MFMUpdated Oct 6, 2026

Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma

An interventional study of Immediate intervention and Waitlist in Multiple Myeloma (MM), sponsored by Medical College of Wisconsin. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 6, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Multiple Myeloma by Medical College of Wisconsin — 7 open to participants now, 9 under way, none of them phase 3. Multiple Myeloma · Medical College of Wisconsin.

Planned enrollment
Largest of 17
184 · median 30
Started
2026
with 3 others
No phase
2 of 19
1 open now
Registered
19th of 19
by date

Among the 19 studies in Multiple Myeloma by Medical College of Wisconsin, this one has the largest planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 with no phase, and was the 19th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

7 of the 19 studies in Multiple Myeloma by Medical College of Wisconsin are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Multiple Myeloma by Medical College of Wisconsin, or all of them as a file.
02

Study summary

The purpose of this project is to evaluate the impact of a 16-week lifestyle program that promotes changes in eating and exercise patterns. The main questions the study will answer are:

Do improvements in eating and exercise patterns lead to improved physical function, quality of life and blood biomarkers of biologial aging among individuals with multiple myeloma? Participants will complete study activities 3-4 times during the study.

  1. In-person assessment to measure physical function, height/weight, body composition, and includes a blood draw
  2. Surveys completed online or on paper at home
Read the detailed description

The study uses a randomized, waitlist control design. Following baseline data collection, participants will be randomized to either the immediate lifestyle intervention group or the waitlist control group. Those who are randomized to the waitlist control group will receive the intervention after the 16-week data collection time point.

03

Conditions studied

  • Multiple Myeloma (MM)

Browse trials for

Keywords

  • Lifestyle Intervention
04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult (≥ 18 years)
  2. Diagnosed with MM at least one year prior to study enrollment
  3. 100 days post transplant (if applicable)
  4. Has access to a smart phone or device with internet access
  5. Be deemed "clinically stable" by their physician guided by the following:

    1. not expected to receive therapies beyond maintenance (for 100 days)
    2. no new significant myeloma symptoms (e.g., fractures, spinal stability concerns) meriting changes in anti-neoplastic therapies in the next 30 days; AND
    3. stable performance status ( 0-2) assessed in the last 3 months
  6. No reports of severe pain > Grade 3 [defined by the as tumor, neurologic, bone, or other pain interfering with self-care ADLs (bathing, dressing, toileting, continence, feeding)].
  7. Able to participate in PA and strength training per clinician approval and confirmed by participant
  8. Able to understand and willing to sign a written document
  9. English proficient for reading and writing

Exclusion criteria

Exclusion Criteria:

  1. Coexistent amyloidosis, POEMS syndrome will not be approached
  2. Fully adherent to the ACS nutrition and physical activity guidelines
  3. If participant is of child-bearing age they cannot be pregnant, planning to come pregnant or lactating during the study period
  4. On another interventional clinical trial that precludes co-enrollment
  5. Psychiatric or other clinical conditions that preclude study compliance
  6. Other important medical or safety considerations at the discretion of the investigator(s) and/or approving clinician
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
184 participants (estimated)

Study arms

  • Experimental
    Immediate Intervention

    16-session intervention that facilitates changes in nutrition and physical activity behaviors to promote improvements in physical function, Patient Reported Outcomes, body composition and general health. The intervention targets plant-based eating, increasing physical activity and strength training.

    Behavioral: Immediate intervention

  • Active comparator
    Waitlist control

    Participants will be asked to maintain their behavior over the 16 week waitlist period and will receive weekly text message relating positive messages unrelated to lifestyle.

    Behavioral: Immediate intervention · Other: Waitlist

Interventions

  • BehavioralImmediate intervention

    16-session intervention that facilitates changes in nutrition and physical activity behaviors to promote improvements in physical function, Patient Reported Outcomes, body composition and general health

  • OtherWaitlist

    Participants will be asked to maintain their behavior over the 16 week waitlist period and will receive weekly text message relating positive messages unrelated to lifestyle

06

What researchers measure

Primary outcomes

  1. Examine the efficacy of the intervention in producing post-intervention changes in performance-based physical function

    Changes in performance-based physical function between the interventional and control groups will be measured using the Short Physical Performance Battery (SPPB), which comprises a 4-meter walk test to assess gait speed, sit-to-stand test to assess lower body strength, and standing balance tests to assess balance. Scoring for the SPPB ranges from 0 to 12; higher scores indicate higher function.

    Time frame: Baseline, Week 16, Week 32, Week 48

Secondary outcomes

  1. Examine the efficacy of the intervention in producing post-intervention changes in patient-reported outcomes.

    Changes in patient-reported outcomes between the interventional and control groups will be measured using: the Patient Reported Outcomes Measurement Information System (PROMIS) physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, pain intensity, satisfaction with social roles and activities, instrumental support, informational support, emotional support, companionship, cognitive function and social isolation. The PROMIS measures for this study will be used in a CAT Computer adaptive format.

    Time frame: Baseline, Week 16, Week 32, Week 48

  2. • Godin Leisure Physical Activity:

    A tool querying about light, moderate, strenuous activities over 7-days and one item asking about strength training

    Time frame: Baseline, Week 16, Week 32, Week 48

  3. • ASA 24-hour Dietary Recall (DR).

    Supported by the National Cancer Institute's ASA24 and with administrative assistance, a minimum of 2 unannounced 24DR will be completed pre/post-intervention using the 5-pass dietary recall methodology.

    Time frame: Baseline, Week 16, Week 32, Week 48

  4. • Self-Efficacy for Eating and Exercise Behaviors:

    A validated tool consisting of 12 items to assess exercise self-efficacy and 20 items to assess healthy eating and exercise self-efficacy

    Time frame: Baseline, Week 16, Week 32, Week 48

  5. Fruit and Vegetable Intake - objective measure

    • Veggie meter- Participants will be asked to complete reflective spectroscopy using the Veggie Meter; a device that non-invasively measures the level of carotenoid pigments in the skin.

    Time frame: Baseline, Week 16, Week 32, Week 48

  6. Outcome Expectancy.

    • Measures positive and negative outcome expectations ("I would sleep more soundly if I exercised regularly"; "Regular exercise would increase my pain.") Higher scores indicate greater positive or negative outcome expectations.

    Time frame: Baseline, Week 16, Week 32, Week 48

  7. Resilience

    • The Brief Resilience Scale (BRS) is a psychological measure designed to quantify a person's ability to 'bounce back' or recover from stressful events or trauma

    Time frame: Baseline, Week 16, Week 32, Week 48

  8. Body composition

    • DEXA imaging is a 10-minute, noninvasive technique that provides precise whole-body measures of fat (total and visceral) and lean mass. Certified DXA technologists will perform and analyze whole body measures using the same machine for each participant at each time point)

    Time frame: Baseline, Week 16, Week 32, Week 48

  9. Objective Physical Activity. (ActivPal):

    • Participants wear this device on the right thigh, held on by a Tegaderm patch to measure PA and sedentary time. Data are downloaded using ActiLife software and will be analyzed using recommended thresholds for moderate and vigorous PA.

    Time frame: Baseline, Week 16, Week 32, Week 48

  10. Lipids and Glucose

    Utilizing clinical resources at MCW or LUC phlebotomy will be performed by trained personnel to conduct fasting blood draws and blood processing according to standard procedures. Whole blood will be collected, allowed to clot for 20 mins, and centrifuged at 2,500 rpm for 20 mins. o Lipids (HDL, LDL, Total Cholesterol, Triglycerides) and glucose measures will be procured using the Choletech LDX (Abbott, Inc.)

    Time frame: Baseline, Week 16, Week 32, Week 48

Other outcomes

  1. Inflammation

    Examine the associations between lifestyle behaviors and serum biomarkers for inflammation. Markers of inflammation including CRP, IL-6; TNF-alpha will be analyzed (blind to randomization) in batch at the end of data collection using commercially available ELISA kits. Each sample will be assayed in duplicate and repeated if variability exceeds 15%.

    Time frame: Baseline, Week 16, Week 32, Week 48

  2. Biological Aging

    o Biological Aging/Cellular Senescence. Additional blood samples will be collected in PAXgene RNA (2.5 mL) tubes and stored (-80° C). Cellular senescence will be assessed via transcript abundance of the p16INK4a- and p21-encoding genes (CDKN2A and CDKN1A, respectively).23-25 A priori-defined sets of genes known to be up-regulated during the DNA damage response (DDR; 30 genes; e.g., CHEK1, SIRT1, TP53, TERF2), and the senescence-associated secretory phenotype (SASP; 61 genes; e.g., IL1A, IL13, CXCL8, CSF2, VEGF) will also be assessed.

    Time frame: Baseline, Week 16, Week 32

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data on participant characteristics and outcomes will be shared.

Supporting information: Study protocol

Time frame: Once the study is completed, de-identified data collected during the study will be made available.

Access criteria: Once the study is completed, de-identified data collected during the study will be deposited in the Harvard Dataverse. Raw RNA-seq, alignment, and transcript data will be made available to the research community free of charge through GEO. Since the purpose of this data sharing is to answer questions in the future, your

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 46 months after the start.

Of 172 non-industry interventional studies with no phase under Multiple Myeloma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 81. This study's planned 46 months is above that.

Counting every sponsor, half of 186 studies reached it within 38 months; a quarter within 20 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2025
First posted
Nov 19, 2025
StartActual
Jan 30, 2026
Primary completionEst.
Dec 15, 2029
CompletionEst.
Feb 28, 2030
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
4 inclusion criteria edited, 2 added, 1 removed; 1 exclusion criterion edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • Added100 days post transplant (if applicable)
  • EditedHas access to a cellsmart phone or device with internet access
  • Removedno near-term changes in planned myeloma-directed therapy anticipated. (e.g., patient who is 3 months from autologous stem cell transplant just starting on maintenance lenalidomide is eligible since maintenance is planned therapy following transplant)
  • Addednot expected to receive therapies beyond maintenance (for 100 days)
  • Editedno new significant myeloma symptoms (e.g., fractures, spinal stability concerns) meriting changes in anti-neoplastic therapies in the next 30 days; AND
  • Editedstable performance status (ECOG 0-2) assessed in the last 3 months
  • EditedAble to participate in moderate PA and strength training per clinician approval and confirmed by participant
Exclusion criteria
  • ChangedBefore Individuals with <6 months of life anticipated, coexistent amyloidosis, and/or receiving appetite stimulants will not be approachedNow Coexistent amyloidosis, POEMS syndrome will not be approached
  • RemovedCurrently pregnant or lactating, or anticipating pregnancy
  • AddedIf participant is of child-bearing age they cannot be pregnant, planning to come pregnant or lactating during the study period
Oct 6, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Loyola University Chicago · Maywood, United StatesContact added p•••@luc.edu · •••9912
  • Medical College of Wisconsin · Milwaukee, United StatesContact added m•••@mcw.edu · •••2377
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Eligibility 4 inclusion criteria edited, 2 added, 1 removed; 1 exclusion criterion edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • Added100 days post transplant (if applicable)
    • EditedHas access to a cellsmart phone or device with internet access
    • Removedno near-term changes in planned myeloma-directed therapy anticipated. (e.g., patient who is 3 months from autologous stem cell transplant just starting on maintenance lenalidomide is eligible since maintenance is planned therapy following transplant)
    • Addednot expected to receive therapies beyond maintenance (for 100 days)
    • Editedno new significant myeloma symptoms (e.g., fractures, spinal stability concerns) meriting changes in anti-neoplastic therapies in the next 30 days; AND
    • Editedstable performance status (ECOG 0-2) assessed in the last 3 months
    • EditedAble to participate in moderate PA and strength training per clinician approval and confirmed by participant
    Exclusion criteria
    • ChangedBefore Individuals with <6 months of life anticipated, coexistent amyloidosis, and/or receiving appetite stimulants will not be approachedNow Coexistent amyloidosis, POEMS syndrome will not be approached
    • RemovedCurrently pregnant or lactating, or anticipating pregnancy
    • AddedIf participant is of child-bearing age they cannot be pregnant, planning to come pregnant or lactating during the study period
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Loyola University Chicago · Maywood, United StatesContact added p•••@luc.edu · •••9912
    • Medical College of Wisconsin · Milwaukee, United StatesContact added m•••@mcw.edu · •••2377

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07236502
Collaborators
National Cancer Institute (NCI), Loyola University Chicago
Responsible party
Melinda Stolley (Principal Investigator, Medical College of Wisconsin) — Principal investigator
First posted
Nov 19, 2025
Start date
Jan 30, 2026
Primary completion
Dec 15, 2029 (estimated)
Completion
Feb 28, 2030 (estimated)
Last update
Oct 6, 2026

Study contacts

Melinda Stolley, PhD
Contact
mstolley@mcw.edu
(312)735-6044
Melinda Stolley, PhD
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion